title: Sarcoidosis complicating treatment with natalizumab for Crohn's disease.
abstract: Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary involvement is reported in two patients with refractory CD who had received maintenance therapy with natalizumab. This complication has not been previously reported. It is hypothesised that the effect of natalizumab in altering lymphocyte mucosal trafficking may underlie the development of sarcoidosis in these patients.
authors.affiliation: Gastrointestinal Unit, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. j.satsangi@ed.ac.uk.
authors.forename: C A
authors.initials: CA
authors.lastname: Parisinos
authors.forename: C W
authors.initials: CW
authors.lastname: Lees
authors.forename: W A H
authors.initials: WA
authors.lastname: Wallace
authors.forename: J
authors.initials: J
authors.lastname: Satsangi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D001706:Biopsy; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D000069442:Natalizumab; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab